ExeVir’s Covid-19 therapy shows neutralisation against omicron variants
ExeVir’s antibody therapy, XVR012, has shown neutralisation potency with an IC50 range of 0.8-1.8 against all SARS-CoV-2 variants including E.G.5.1, HV.1 and BA.2.86.1.
Explore our marketing solutions
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
